Gan & Lee Pharmaceuticals.
603087
Rangering i aksjer
#3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aksjekurs
$10.03
Markedsverdi
$5.99B
Endring (1 dag)
-3.71%
Endring (1 år)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
P/S-forhold for Gan & Lee Pharmaceuticals. (603087)
P/S-forhold per October 2026 TTM: 9.51
Ifølge Gan & Lee Pharmaceuticals. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 9.51. Ved slutten av 2024 hadde selskapet et P/S-forhold på 8.56.
P/S-historikk for Gan & Lee Pharmaceuticals. fra 2013 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 9.51 | -4.69% |
| 2025 | 9.98 | 16.64% |
| 2024 | 8.56 | -25.20% |
| 2023 | 11.44 | 7.09% |
| 2022 | 10.68 | -2.29% |
| 2021 | 10.94 | -50.49% |
| 2020 | 22.08 | 74.82% |
| 2019 | 12.63 | -8.28% |
| 2018 | 13.77 | -0.87% |
| 2017 | 13.89 | -25.30% |
| 2016 | 18.60 | -31.05% |
| 2015 | 26.97 | -23.67% |
| 2014 | 35.34 | -20.02% |
| 2013 | 44.18 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 13.45 | 41.45% |
US
|
|
| 2.32 | -75.56% |
FR
|
|
| - | - |
JP
|
|
| 2.47 | -74.04% |
US
|
|
| - | - |
CH
|
